BNF:

3.1.2

Status:

Grey, Grey - after consultant/specialist initiation

Decision Date:

None

Comments

GREY:

• Single component LAMA are no longer recommended as first line treatment option. COPD patients should be treated with LABA+LAMA inhaler or consider LABA+ICS inhaler if patient has asthmatic features or features suggesting steroid responsiveness. See JAPC COPD guideline.
• Tiotropium (Tiogiva or Spiriva Respimat) is the preferred LAMA if treatment with single component LAMA is required. (Decision date - March 2023)
• Following on from a MHRA drug safety update (Feb 2015), prescribers should take the risk of CV side effects into account when prescribing tiotropium via a handihaler or a respimat or Tiogiva for patients with certain cardiac conditions. Consult the SPC for further details. (Decision date - March 2015).

GREY after consultant/specialist initiation:

• for asthma. Severe asthma with a demonstrated airflow obstruction. Spiriva Respimat (Decision date - December 2014)

 

search again